Maximus - MMS Stock Forecast, Price & News

Maximus' stock was trading at $79.67 at the beginning of the year. Since then, MMS shares have decreased by 27.4% and is now trading at $57.87.
View the best growth stocks for 2022 here.

Maximus saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,810,000 shares, an increase of 12.4% from the August 31st total of 1,610,000 shares. Based on an average trading volume of 348,500 shares, the short-interest ratio is presently 5.2 days. Approximately 3.0% of the company's shares are short sold.
View Maximus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 17th 2022.
View our MMS earnings forecast.

Maximus, Inc. (NYSE:MMS) posted its quarterly earnings data on Wednesday, August, 3rd. The health services provider reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.98 by $0.20. The health services provider had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. Maximus had a net margin of 4.10% and a trailing twelve-month return on equity of 16.59%.

Maximus declared a quarterly dividend on Tuesday, July 12th. Stockholders of record on Monday, August 15th will be paid a dividend of $0.28 per share on Wednesday, August 31st. This represents a $1.12 annualized dividend and a yield of 1.94%. The ex-dividend date of this dividend is Friday, August 12th.
Read our dividend analysis for MMS.

Maximus (NYSE:MMS) pays an annual dividend of $1.12 per share and currently has a dividend yield of 1.93%. The dividend payout ratio is 37.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MMS will have a dividend payout ratio of 23.58% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MMS.

Maximus issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of $3.95-$4.15 for the period, compared to the consensus earnings per share estimate of $3.04. The company issued revenue guidance of $4.55 billion-$4.65 billion, compared to the consensus revenue estimate of $4.51 billion.

145 employees have rated Maximus Chief Executive Officer Bruce Caswell on Glassdoor.com. Bruce Caswell has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Maximus investors own include Pfizer (PFE), Lennar (LEN), AbbVie (ABBV), Cisco Systems (CSCO), Kroger (KR), Skyworks Solutions (SWKS), Advanced Micro Devices (AMD), Cerner (CERN), Intel (INTC) and JD.com (JD).

Maximus trades on the New York Stock Exchange (NYSE) under the ticker symbol "MMS."

Shares of MMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MMS stock can currently be purchased for approximately $57.87.

Maximus (NYSE:MMS) has a market capitalization of $3.55 billion and generates $4.25 billion in revenue each year. The health services provider earns $291.20 million in net income (profit) each year or $2.99 on an earnings per share basis.

The company employs 35,800 workers across the globe.

Maximus' mailing address is 1891 METRO CENTER DRIVE, RESTON VA, 20190. The official website for the company is www.maximus.com. The health services provider can be reached via phone at (703) 251-8500, via email at investorrelations@maximus.com, or via fax at 703-251-8240.